Prevention of hypertension and organ damage in 2-kidney, 1-clip rats by tetradecylthioacetic acid.
Dietary lipids are reported to affect the blood pressure in both humans and experimental animal models with hypertension. In the present study, 2-kidney, 1-clip (2K1C) hypertensive rats were treated with the modified fatty acid tetradecylthioacetic acid (TTA) from the time of clipping or after hypertension was established. TTA treatment attenuated the development of hypertension and reduced established 2K1C hypertension. The mRNA level of renin in the clipped kidney and the plasma renin activity were markedly reduced, and the plasma angiotensin II level tended to decrease after TTA treatment. In addition, TTA reduced the mRNA level of angiotensinogen in white adipose tissue. Prevention of organ damage was demonstrated by normal urinary excretion of protein, maintained serum albumin, lower heart weight, and clearly reduced vascular, glomerular, and tubulointerstitial damage in the nonclipped kidney. Renal function was not affected as estimated by unchanged plasma creatinine. Furthermore, the serum levels of triacylglycerol and cholesterol were reduced by TTA. The serum fatty acid composition was changed, resulting in a favorable increase of oleic acid. However, the levels of all of the omega-3 fatty acids and of linoleic acid were reduced, and no change was seen in the level of arachidonic acid, but the urinary excretion of 8-iso-prostaglandin F2alpha was declined. In conclusion, TTA attenuated the development of hypertension, reduced established hypertension, and prevented the development of organ damage in 2K1C rats, possibly by reducing the amounts of the vasoconstrictors angiotensin II and 8-iso-prostaglandin F2alpha and by inducing a favorable increase of oleic acid in serum.
Gudbrandsen
Oddrun Anita
OA
Lipid Research Group, Institute of Medicine, University of Bergen, Bergen Norway.
Hultstrøm
Michael
M
Leh
Sabine
S
Monica Bivol
Liliana
L
Vågnes
Øyvind
Ø
Berge
Rolf K
RK
Iversen
Bjarne M
BM
D000419:Albuminuria / Q000503:physiopathology; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000097:blood; D000818:Animals; D001808:Blood Vessels / Q000473:pathology; D015237:Dinoprost / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000097:blood; D005227:Fatty Acids / Q000097:blood / Q000378:metabolism; D006978:Hypertension, Renovascular / Q000473:pathology / Q000503:physiopathology* / Q000517:prevention & control*; D007668:Kidney / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000378:metabolism; D008297:Male; D019301:Oleic Acid / Q000097:blood; D011507:Proteinuria / Q000503:physiopathology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012083:Renin / Q000097:blood / Q000235:genetics; D013440:Sulfides / Q000494:pharmacology*; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors / Q000097:blood
D005227:Fatty Acids; D012333:RNA, Messenger; D013440:Sulfides; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; C075750:8-epi-prostaglandin F2alpha; D019301:Oleic Acid; C062078:1-(carboxymethylthio)tetradecane; D015237:Dinoprost; D012083:Renin